Chronic liver disease (CLD) has a dismal prognosis, with an overall low survival rate. Albumin is demonstrated as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis. Long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites. Takeda and Docplexus have organized an interactive LIVE webinar on 24th March 2022, from 7:00 PM onwards . Please join our expert; Dr.
Abdul Ansari, Dr. Pradeep Rangappa, and Dr. Vijay Kumar Mishra who will be sharing their insights on "Current trends of albumin usage in acute ill patients of CLD.” Stay tuned for the insightful session! VV-MEDMAT-65267 Disclaimer * This is a Takeda…
